<GlossaryTerm id="CDR0000795025"><TermName>dacomitinib</TermName><TermPronunciation>(DA-koh-MIH-tih-nib)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat non-small cell lung cancer that has spread, has not already been treated, and has certain mutations (changes) in the <GeneName>EGFR</GeneName> gene. It is also being studied in the treatment of other types of cancer. Dacomitinib blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called PF-00299804 and Vizimpro.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000796109" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;dacomitinib&quot;" language="en" id="_3"/><MediaLink ref="CDR0000796108" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;dacomitinib&quot;" language="es" id="_4"/><SpanishTermName>dacomitinib</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento del cáncer de pulmón  de células no pequeñas que se diseminó, no se ha tratado y presenta ciertas mutaciones (cambios) en el gen <GeneName>EGFR</GeneName>. También está en estudio para el tratamiento de otros tipos de cáncer. El dacomitinib bloquea ciertas proteínas, lo que quizás ayude a evitar la multiplicación de células cancerosas y las destruya. Es un tipo de inhibidor de  tirosina–cinasas. También se llama PF-00299804 y Vizimpro.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2018-10-02</DateFirstPublished><DateLastModified>2021-10-21</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000795301" url="/about-cancer/treatment/drugs/dacomitinib">Dacomitinib</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
